LUYE PHARMA's innovative formulation ERZOFRI®, independently developed, has been approved by the FDA for the treatment of schizophrenia and schizoaffective disorder
I'm PortAI, I can summarize articles.
LUYE PHARMA's self-developed innovative formulation ERZOFRI® has been approved by the FDA for the treatment of schizophrenia and schizoaffective disorder. This is the first long-acting injection of paliperidone palmitate developed by a Chinese company, administered once a month. The product is expected to provide patients with a new treatment option
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments